APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03175224|
Recruitment Status : Recruiting
First Posted : June 5, 2017
Last Update Posted : May 10, 2022
The primary Phase 1 purpose of this study was to assess overall safety, tolerability and recommended Phase 2 dose (RP2D) of APL-101.
The Phase 2 portion will assess efficacy of the dose determined in Phase 1 in individuals with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations; individuals with cancers associated with c-Met amplifications; individuals with cancers associated with c-Met fusion
|Condition or disease||Intervention/treatment||Phase|
|Solid Tumor Advanced Cancer Renal Cancer Gastric Cancer Gastroesophageal Junction Adenocarcinoma NSCLC Lung Cancer Brain Tumor Glioblastoma Multiforme||Drug: APL-101 Oral Capsules||Phase 1 Phase 2|
This is a Phase 1/2, multi-center, global, open-label, 2-part study with a Dose Escalation Segment and Dose and Disease Expansion Cohorts study of APL-101, a c-MET inhibitor, to determine the recommended Phase 2 dose (RP2D) and dose limiting toxicities for APL-101, and to obtain preliminary efficacy and target engagement data, in subjects with NSCLC and advanced malignancies with c-Met dysregulation.
c-MET dysregulation will be determined from historical results by molecular pre-screening evaluations to determine eligibility of enrollment for both the Dose Escalation Segment (Phase 1) and Dose and Disease Expansion Cohorts (Phase 2).
Dose escalation will occur until a protocol defined dose limited toxicity (DLT) occurs and a tentative maximum tolerated dose (MTD) is determined.
Once dose is determined, seven cohort groups will be further evaluated:
- Cohort A-1: NSCLC EXON 14 skip mutation (c-Met naïve, 1L)
- Cohort A-2: NSCLC EXON 14 skip mutation (c-Met naïve, 2/3L),
- Cohort B: NSCLC EXON 14 skip mutation (c-Met experienced; progressed on prior c-Met inhibitor),
- Cohort C: basket of tumor types except primary CNS tumors with c-Met high-level amplifications (MET inhibitor naive)
- Cohort C-1:NSCLC harboring MET amplification and wild-type EGFR (MET inhibitor naive)
- Cohort D: basket of tumor types except primary CNS tumors harboring c-Met fusions (MET inhibitor naive)
- Cohort E: Primary CNS tumors with MET alterations (MET inhibitor naive)
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||344 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||
Phase 1: Subjects will be assigned to a dose level in the order of study entry. Treatment includes four planned dose levels (100 mg, 200 mg, 300 mg, and 400 mg).
Phase 2: Subjects will receive RP2D at 400mg daily dose (200mg BID). In Cohort E, the dose may be increased up to 300 mg BID starting at C2D1.Subjects with prior IO therapy within 90 days of study drug start will start at 100mg BID.
|Masking:||None (Open Label)|
|Masking Description:||Open Label|
|Official Title:||Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors|
|Actual Study Start Date :||September 27, 2017|
|Estimated Primary Completion Date :||March 30, 2026|
|Estimated Study Completion Date :||November 30, 2026|
APL-101 Oral Capsules
Drug: APL-101 Oral Capsules
Phase 1 Subjects will be assigned to a dose level of APL-101 in the order of study entry. Treatment includes 28-day cycles at four planned dose levels (100mg, 200mg, 300mg and 400mg). Each treatment cycle is administered by daily oral capsules taken every 12 hours.
Phase 2 Subjects will be given 400mg daily dose (200mg BID) of APL-101 capsules.
- Estimate the maximum tolerated dose (MTD) and the incidence of DLTs in Phase 1 (Completed) [ Time Frame: From the time of informed consent signature through Cycle 1 (28 days) completion ]Adverse events, serious adverse events, and dose limiting toxicities
- Objective response rate (ORR = CR + PR) per blinded independent review committee (BIRC) based on RECIST v1.1 (or relevant criteria per tumor type) [ Time Frame: From time of informed consent signature through completion of treatment (1 cycle = 28 days) ]Anti-tumor activity per RECIST v1.1 or relevant evaluation criteria per tumor type.
- Median duration of response (DOR) per BIRC. [ Time Frame: Approximately 2 years ]DOR per RECIST v1.1 or relevant evaluation criteria per tumor type.
- ORR per investigator assessment based on RECIST v1.1. [ Time Frame: Approximately 2 years ]ORR per RECIST v1.1 or relevant evaluation criteria per tumor type.
- Median DOR per investigator assessment. [ Time Frame: Approximately 2 years ]DOR per RECIST v1.1 or relevant evaluation criteria per tumor type.
- Antitumor activity by clinical benefit rate (CR + PR + SD ≥ 4 cycles) based on RECIST v1.1 Median time to progression (TTP). [ Time Frame: Approximately 2 years ]Benefit rate per RECIST v1.1 or relevant evaluation criteria per tumor type.
- Median time to progression (TTP). [ Time Frame: Approximately 2 years ]TTP per RECIST v1.1 or relevant evaluation criteria per tumor type.
- Progression Free Survival (PFS) and overall survival (OS) at 6, 12, 18 and 24 months [ Time Frame: Approximately 3 years ]PFS and OS per RECIST v1.1 or relevant evaluation criteria per tumor type.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03175224
|Contact: Ayala Luria, Ph.D.||firstname.lastname@example.org|
|Contact: Anna Nekhymchukemail@example.com|
|Principal Investigator:||Mark Awad, M.D.||Dana-Farber Cancer Institute|